ストックスクリーナーアプリを入手
1.23
1.65%
0.02
前日終値:
$1.21
開ける：
$1.21
24時間の取引高:
266.94K
Relative Volume:
0.24
時価総額：
$75.58M
収益：
$5.03M
当期純損益:
$-185.41M
株価収益率:
-0.3981
EPS:
-3.09
ネットキャッシュフロー:
$-139.79M
1週間 パフォーマンス:
+0.82%
1か月 パフォーマンス:
-21.66%
6か月 パフォーマンス:
-5.38%
1年 パフォーマンス:
-90.88%
1日の値動き範囲:
$1.19
$1.24
1週間の範囲:
$1.19
$1.27
52週間の値動き範囲:
$1.1001
$14.26
Pliant Therapeutics Inc Stock (PLRX) Company Profile
名前
Pliant Therapeutics Inc
セクター
電話
650-481-6770
住所
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
PLRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PLRX
Pliant Therapeutics Inc
|
1.23 | 74.35M | 5.03M | -185.41M | -139.79M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.99 | 116.51B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.71 | 82.52B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.69 | 52.67B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
849.95 | 52.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.42 | 37.70B | 447.02M | -1.18B | -906.14M | -6.1812 |
Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-10 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2025-03-04 | 再開されました | Cantor Fitzgerald | Neutral |
| 2025-03-04 | ダウングレード | Needham | Buy → Hold |
| 2025-03-03 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-03-03 | ダウングレード | Stifel | Buy → Hold |
| 2025-02-10 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2025-02-10 | ダウングレード | Citigroup | Buy → Neutral |
| 2025-02-10 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2025-02-10 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2025-02-10 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2025-02-10 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-10 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-09-09 | 再開されました | Leerink Partners | Outperform |
| 2023-12-08 | 開始されました | Wells Fargo | Overweight |
| 2023-05-18 | 開始されました | Canaccord Genuity | Buy |
| 2023-04-13 | 開始されました | Robert W. Baird | Outperform |
| 2022-12-14 | 開始されました | Stifel | Buy |
| 2022-12-07 | 開始されました | JP Morgan | Overweight |
| 2022-09-01 | 開始されました | Citigroup | Buy |
| 2022-07-20 | 開始されました | SVB Leerink | Outperform |
| 2022-05-25 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-12-10 | 開始されました | Oppenheimer | Outperform |
| 2021-11-24 | 開始されました | RBC Capital Mkts | Outperform |
| 2021-11-03 | 開始されました | H.C. Wainwright | Buy |
| 2021-04-20 | 開始されました | BTIG Research | Buy |
| 2021-04-05 | 開始されました | Citigroup | Buy |
| 2020-06-29 | 開始されました | Citigroup | Buy |
| 2020-06-29 | 開始されました | Cowen | Outperform |
| 2020-06-29 | 開始されました | Needham | Buy |
| 2020-06-29 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Pliant Therapeutics Inc (PLRX) 最新ニュース
Can Pliant Therapeutics Inc. stock double in next 5 yearsTrade Volume Summary & Long-Term Safe Investment Ideas - DonanımHaber
Pliant Therapeutics appoints Minnie Kuo as COO - MSN
Is Pliant Therapeutics Inc. (9PT) stock prepared for digital transition2025 Buyback Activity & Verified Chart Pattern Signals - Улправда
Is Pliant Therapeutics Inc a good long term investmentHead and Shoulders Patterns & Free Professional Investment Consultations - earlytimes.in
What analysts say about Pliant Therapeutics Inc stockStock Screening Results & Free Explosive Wealth Accumulation - earlytimes.in
Pliant Therapeutics appoints Minnie Kuo as chief operating officer By Investing.com - Investing.com Nigeria
Pliant Therapeutics appoints Minnie Kuo as chief operating officer - Investing.com
Pliant Therapeutics Appoints Minnie Kuo as COO - TipRanks
Pliant Therapeutics Appoints New Chief Operating Officer - TradingView — Track All Markets
Pliant Therapeutics (NASDAQ: PLRX) names Minnie Kuo Chief Operating Officer - Stock Titan
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Average Rating of “Reduce” by Brokerages - Defense World
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Average Rating of "Reduce" by Brokerages - MarketBeat
Pliant Therapeutics, Inc. (PLRX) Presents at Piper Sandler 37th Annual Healthcare ConferenceSlideshow - Seeking Alpha
Pliant Therapeutics to end employment of chief medical officer Dr. Éric Lefebvre - Investing.com Nigeria
Pliant Therapeutics Announces Departure of Chief Medical Officer - TradingView
Pliant Therapeutics Inc (PLRX) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - Setenews
Pliant Therapeutics to end employment of chief medical officer Dr. Éric Lefebvre By Investing.com - Investing.com South Africa
Pliant Therapeutics shares rise after early cancer drug data impresses - MSN
Pliant Therapeutics (PLRX) Stock Analysis Report | Financials & Insights - Benzinga
Pliant Therapeutics reports interim PLN-101095 Phase I trial data - Yahoo
Pliant’s PLN-101095 shows promising results in cancer trial By Investing.com - Investing.com Nigeria
Can Pliant Therapeutics Inc. stock sustain revenue growthJuly 2025 PreEarnings & Real-Time Volume Trigger Notifications - Newser
Analysts Offer Insights on Healthcare Companies: Pliant Therapeutics (PLRX), uniQure (QURE) and Medtronic (MDT) - The Globe and Mail
What hedge fund moves indicate for Pliant Therapeutics Inc. (9PT) stockJuly 2025 Review & Free Safe Capital Growth Stock Tips - Newser
Can Pliant Therapeutics Inc. (9PT) stock double in coming yearsJuly 2025 Snapshot & Risk Controlled Daily Trade Plans - Newser
Why Pliant Therapeutics Inc. (9PT) stock could be top winnerBear Alert & Risk Controlled Daily Plans - Newser
Why Is Pliant Therapeutics Stock Trading Lower TodayPliant Therapeutics (NASDAQ:PLRX) - Benzinga
Pliant Therapeutics, Inc. (PLRX) -15.3% in Intraday Trading: Interim Data Announcement Fails to Support Price - Stocks Telegraph
Pliant Therapeutics stock jumps on promising cancer drug trial results By Investing.com - Investing.com South Africa
Pliant Therapeutics stock jumps on promising cancer drug trial results - Investing.com
Pliant Therapeutics, Inc. Announces Interim Data from Pln-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors - marketscreener.com
Pliant’s PLN-101095 shows promising results in cancer trial - Investing.com India
Pliant Therapeutics reveals promising early results for PLN-101095 - Traders Union
Pliant Therapeutics announces interim data from PLN-101095 - marketscreener.com
Pliant Therapeutics (Nasdaq: PLRX) reports interim PLN-101095 data with 1 CR, 3 PRs - Stock Titan
Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors - Sahm
Is Pliant Therapeutics Inc. (9PT) stock considered safe havenTrade Volume Report & Community Consensus Stock Picks - Newser
Are Smart Investors Making the Right Decision? Pliant Therapeutics Inc (PLRX) - setenews.com
Will Pliant Therapeutics Inc. (9PT) stock profit from fiscal stimulusMarket Risk Summary & Verified Swing Trading Watchlist - Newser
Will Pliant Therapeutics Inc. stock attract more institutional investors - Newser
Pliant Therapeutics to Participate in the Piper Sandler Healthcare Conference - Investing News Network
Pliant Therapeutics Inc Stock Analysis and ForecastRSI Overbought/Oversold & Insights From Wall Street Professionals - earlytimes.in
What drives Pliant Therapeutics Inc stock priceCapital Gains Strategies & Access Advanced Stock Screening Tools - earlytimes.in
Pliant Therapeutics Inc (PLRX) 財務データ
収益
当期純利益
現金流量
EPS
Pliant Therapeutics Inc (PLRX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Cummings Keith Lamont | Chief Financial Officer |
Jan 17 '25 |
Sale |
11.20 |
20,148 |
225,680 |
262,608 |
| Hull Hans | Chief Business Officer |
Jan 17 '25 |
Sale |
11.20 |
15,936 |
178,501 |
211,558 |
| Lefebvre Eric | Chief Medical Officer |
Jan 17 '25 |
Sale |
11.20 |
18,478 |
206,974 |
194,574 |
| Cheung Lily | Chief Human Resource Officer |
Jan 17 '25 |
Sale |
11.20 |
3,740 |
41,892 |
24,550 |
| Ouimette Mike | General Counsel & Corp. Sec'y |
Jan 17 '25 |
Sale |
11.20 |
13,270 |
148,639 |
80,774 |
| Ouimette Mike | General Counsel & Corp. Sec'y |
Jan 22 '25 |
Sale |
10.99 |
10,230 |
112,462 |
70,544 |
0.36%
0.21%
大文字化:
|
ボリューム (24 時間):